Abstract
Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have shown poor effectiveness in treating peritoneal carcinomatosis (PC) of gastric origin with a high tumor burden (high peritoneal cancer index), though there are scarce therapy alternatives that are able to improve survival. In experimental studies, chimeric antigen receptor-T (CAR-T) cell therapy has shown encouraging results in gastric cancer and is currently being evaluated in several clinical trials. Regarding PC, CAR-T cell therapy has also proven useful in experimental studies, especially when administered intraperitoneally, as this route improves cell distribution and lifespan. Although these results need to be supported by ongoing clinical trials, CAR-T cells are a promising new therapeutic approach to peritoneal metastases from gastric cancer. In this review, we summarize the current evidence of the use of CAR-T cells in gastric cancer and PC of gastric origin.
Highlights
The use of chimeric antigen receptor-T (CAR-T) cells is a new type of a monoclonal antibody that targets this receptor and is mainly used in breast and gastric immunotherapy developed over recent decades and consists of modifying patients’ own cancer, improving patient survival [13,14]
The use of chimeric antigen receptor-T (CAR-T) cells is a new type of immunotherapy vectors, the CAR is introduced into the T cell, which enables the cell to recognize a developed over recent decades and consists of modifying patients’ own T-lymphocytes to selected tumor-associated antigen (TAA) in a major histocompatibility class-independent attack a specific target
Though there are several studies investigating the usefulness of CAR-T in PC, studies focused on peritoneal carcinomatosis from Gastric cancer (GC) are scarce
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. The use of chimeric antigen receptor-T (CAR-T) cells is a new type of a monoclonal antibody that targets this receptor and is mainly used in breast and gastric immunotherapy developed over recent decades and consists of modifying patients’ own cancer, improving patient survival [13,14]. The use of chimeric antigen receptor-T (CAR-T) cells is a new type of immunotherapy vectors, the CAR is introduced into the T cell, which enables the cell to recognize a developed over recent decades and consists of modifying patients’ own T-lymphocytes to selected tumor-associated antigen (TAA) in a major histocompatibility class-independent attack a specific target. TAAs are more in solid tumors, and finding anconsists antigenofthat ment that avertsheterogeneous the action of these cells; this physical barrier stroma and an fits with theimmunologic target selection criteria is difficult [35]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
